Rachel Rennard
Senior Vice President - Research Stereo Biotherapeutics
Rachel Rennard is Senior Vice President of Research at Stereo Biotherapeutics. With over 20 years of experience in protein discovery and engineering, Rachel has driven the development of innovative platforms that advance next-generation therapeutics. Prior to Stereo, Rachel served as Vice President of Research at Mosaic Biosciences, where she expanded and elevated the company’s antibody discovery capabilities to advance external therapeutic partnerships. Earlier, as Chief Technology Officer of Antibodies at Alloy Therapeutics, she architected the company’s discovery platform and led multidisciplinary teams delivering transformative antibody solutions to partners. Rachel is passionate about building and cultivating high-performing teams that thrive on collaboration, creativity, and scientific excellence.
When not working, Rachel can be found mountain biking, skiing, fermenting, and foraging.
Seminars
- Discussing the methodologies currently used to identify antigens in multiple myeloma and B-cell lymphoma
- Debating whether therapeutic failure in hematologic cancers stems from T-cell exhaustion or from a lack of high-density, specific antigens to target
- Identifying shared antigens vs personalized neoantigens in solid tumor populations
- A purpose‑built approach addresses the limiting challenges of narrow therapeutic windows and target heterogeneity by extending T‑cell engager success to pMHC targets.
- Trackers, small soluble TCR‑derived binding elements, leverage the natural pMHC–TCR interaction to drive precise tumor cell killing while maintaining antibody‑like developability.
- The Broadcast platform identifies optimal target pairs, discovers and optimizes novel Trackers with drug‑like properties, and designs multi‑specific formats that expand tumor coverage and increase the number of patients with potential to benefit
